GlassScriptPhysician profile
Rachel Davis
NPI 1285431304
$1,236.01
in general payments reported to CMS, 2019-2025
24 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what 88% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.02 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $163.41 | 2025 | |
| Astellas Pharma US INC | $131.41 | 2025 | Veozah |
| Vanda Pharmaceuticals INC. | $119.68 | 2025 | Hetlioz, Fanapt |
| Pfizer INC. | $116.00 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.23 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.21 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $72.62 | 2025 | |
| Exact Sciences Corporation | $38.74 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $34.07 | 2025 | Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $31.46 | 2025 | Zoryve |
| Corcept Therapeutics | $28.98 | 2025 | Korlym |
| Dexcom, INC. | $28.33 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $28.06 | 2025 | Airsupra, Farxiga |
| Daiichi Sankyo INC. | $26.21 | 2025 | Injectafer |
| Esperion Therapeutics, INC. | $25.51 | 2025 | Nexletol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $25.48 | 2025 | Austedo Xr |
| Viatris Specialty LLC | $23.05 | 2025 | Yupelri |
| Novo Nordisk INC | $22.63 | 2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $22.47 | 2025 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $22.29 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $20.04 | 2025 | Auvelity |
| Boston Scientific Corporation | $19.64 | 2025 | Watchman Access System |
| Amgen INC. | $16.25 | 2025 | Repatha |
| Inspire Medical Systems, INC. | $14.24 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.